Symposia: Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities
	
	
	Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Lymphoid Leukemias, ALL, Adult, Autoimmune hemolytic anemia, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Infusion, Young adult , Human, Study Population, Transplantation (Allogeneic and Autologous)
	Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Autoimmune disorders, Lymphoid Leukemias, ALL, Adult, Autoimmune hemolytic anemia, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Immune Disorders, Treatment Considerations, Biological therapies, Immunology, Lymphoid Malignancies, Infusion, Young adult , Human, Study Population, Transplantation (Allogeneic and Autologous)
Sunday, December 8, 2024: 4:30 PM-6:00 PM
	Marriott Grand Ballroom 2-4 
		(Marriott Marquis San Diego Marina)
	
	
	
	
	   
	
	
			
		Moderators:
			
				
				
					
						
						
						
							Jennifer N Brudno, MD, National Cancer Institute, National Institutes of Health
						
					
					
				
					
						 and 
						
						
							Alexandre V. Hirayama, MD, ARRAY(0xebfe82c)
						
					
					
				
			
 
			
			Disclosures:
			
			
				
			
				
			
			Hirayama: Juno Therapeutics, a Bristol Myers Squibb Company: Honoraria, Research Funding; Nektar Therapeutics: Research Funding. 
			 
		4:30 PM
	
	
4:45 PM
	
	
5:00 PM
	
	
5:30 PM
	
	
	
	
	See more of: Oral and Poster Abstracts
	
	
	
	
	*signifies non-member of ASH
					 
	
	 denotes an abstract that is clinically relevant.
 denotes an abstract that is clinically relevant. denotes that this is a recommended PHD Trainee Session.
 denotes that this is a recommended PHD Trainee Session. denotes that this is a ticketed session.
 denotes that this is a ticketed session.